Accuray Incorporated (NASDAQ:ARAY) saw some unusual options trading on Monday. Investors bought 1,040 call options on the company. This represents an increase of approximately 1,500% compared to the average daily volume of 65 call options.

ARAY has been the subject of a number of recent analyst reports. Jefferies Group LLC decreased their target price on Accuray from $7.00 to $6.00 and set a “buy” rating for the company in a report on Wednesday, August 23rd. Cowen and Company restated a “buy” rating and set a $9.00 target price on shares of Accuray in a report on Friday, October 27th. Zacks Investment Research upgraded Accuray from a “hold” rating to a “buy” rating and set a $4.75 target price for the company in a report on Tuesday, October 24th. BTIG Research restated a “hold” rating on shares of Accuray in a report on Thursday, August 24th. Finally, Royal Bank Of Canada reiterated a “hold” rating and issued a $5.00 price objective on shares of Accuray in a report on Thursday, August 24th. One analyst has rated the stock with a sell rating, four have given a hold rating and three have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $6.29.

Accuray (NASDAQ:ARAY) opened at $5.30 on Thursday. The company has a debt-to-equity ratio of 2.44, a current ratio of 1.48 and a quick ratio of 0.92. Accuray has a twelve month low of $3.60 and a twelve month high of $6.00.

Accuray (NASDAQ:ARAY) last posted its quarterly earnings data on Tuesday, October 24th. The medical equipment provider reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.02. The business had revenue of $91.00 million during the quarter, compared to the consensus estimate of $88.26 million. Accuray had a negative return on equity of 55.18% and a negative net margin of 7.49%. The firm’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.12) earnings per share. analysts predict that Accuray will post -0.18 EPS for the current fiscal year.

In related news, COO Kelly Londy sold 99,136 shares of the company’s stock in a transaction that occurred on Wednesday, October 4th. The stock was sold at an average price of $4.24, for a total transaction of $420,336.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 3.90% of the stock is owned by corporate insiders.

Several large investors have recently modified their holdings of the company. Neuberger Berman Group LLC increased its holdings in shares of Accuray by 9.9% during the third quarter. Neuberger Berman Group LLC now owns 5,272,695 shares of the medical equipment provider’s stock valued at $21,091,000 after acquiring an additional 473,008 shares in the last quarter. Vident Investment Advisory LLC increased its holdings in shares of Accuray by 75.4% during the third quarter. Vident Investment Advisory LLC now owns 4,899,643 shares of the medical equipment provider’s stock valued at $19,599,000 after acquiring an additional 2,106,215 shares in the last quarter. Sectoral Asset Management Inc increased its holdings in shares of Accuray by 16.9% during the third quarter. Sectoral Asset Management Inc now owns 687,547 shares of the medical equipment provider’s stock valued at $2,750,000 after acquiring an additional 99,200 shares in the last quarter. Wells Fargo & Company MN increased its holdings in shares of Accuray by 52.5% during the third quarter. Wells Fargo & Company MN now owns 94,664 shares of the medical equipment provider’s stock valued at $379,000 after acquiring an additional 32,605 shares in the last quarter. Finally, Wasatch Advisors Inc. increased its holdings in shares of Accuray by 5.9% during the third quarter. Wasatch Advisors Inc. now owns 291,716 shares of the medical equipment provider’s stock valued at $1,167,000 after acquiring an additional 16,216 shares in the last quarter. Hedge funds and other institutional investors own 75.68% of the company’s stock.

WARNING: “Traders Buy Large Volume of Call Options on Accuray (ARAY)” was originally published by Daily Political and is the property of of Daily Political. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at https://www.dailypolitical.com/2017/11/22/traders-buy-large-volume-of-call-options-on-accuray-aray.html.

Accuray Company Profile

Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy.

Receive News & Ratings for Accuray Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.